CDT Equity (CDT) Current Deferred Revenue (2022 - 2023)
CDT Equity's (CDT) quarterly Current Deferred Revenue came in at $1.5 million in Q3 2023, up 7.14% on a QoQ basis from $1.4 million in Q4 2022.
CDT Equity (CDT) Current Deferred Revenue (2022 - 2023) Analysis & Trends
CDT Equity (CDT) has 2 years of Current Deferred Revenue data on file, last reported at $1.5 million in Q3 2023.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $1.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $1.5 million (changed N/A YoY) and the FY2022 annual result came in at $1.4 million, changed N/A from the prior year.
- Current Deferred Revenue rose to $1.5 million in Q3 2023, from $1.4 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.5 million in Q3 2023 to a low of $1.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.40 Mn |